mTOR inhibition induces compensatory, therapeutically targetable MEK activation in renal cell carcinoma

Rapamycin derivatives allosterically targeting mTOR are currently FDA approved to treat advanced renal cell carcinoma (RCC), and catalytic inhibitors of mTOR/PI3K are now in clinical trials for treating various solid tumors. We sought to investigate the relative efficacy of allosteric versus catalyt...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:PloS one 2014-09, Vol.9 (9), p.e104413-e104413
Hauptverfasser: Bailey, Sean T, Zhou, Bing, Damrauer, Jeffrey S, Krishnan, Bhavani, Wilson, Harper L, Smith, Aleisha M, Li, Mingqing, Yeh, Jen Jen, Kim, William Y
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!